OncoSil Medical Completes Manufacturing Validation
Filed with ASX · · 3 pages · English
Summary by 6ix AI
OncoSil Medical Ltd has announced the successful completion of its manufacturing validation program, establishing a scalable production capability in Australia for its OncoSil™ device. This initiative is expected to enhance manufacturing efficiency and improve gross margins while supporting future commercial growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from OncoSil Medical
- OncoSil Medical Files for FDA Approval
- OncoSil Selected for Major European Pancreatic Cancer Study
- OncoSil progresses HDE with US FDA
- OncoSil Medical Receives TGA Approval in Australia
- Security Class Reinstatement to Quotation - OSLOE
Later from OncoSil Medical
- OncoSil Receives FDA Approval for Distal Cholangiocarcinoma
- OSL Secures $5.6 million from Major Institutional Investors
- Australian Manufacturing Facility Achieves ISO 13485
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical